Introduction:
The global cell and gene therapy market is rapidly expanding, with a projected growth rate of 20% annually. As the demand for these advanced therapies continues to rise, contract development and manufacturing organizations (CDMOs) play a crucial role in providing the necessary infrastructure for production. In this report, we will highlight the top 50 major cell and gene therapy CDMOs that are expected to lead the industry by 2026.
Top 50 Major Cell and Gene Therapy Contract Manufacturing Organizations CDMOs 2026:
1. Lonza Group AG:
– Market share: 25%
– Lonza Group AG is a leading CDMO with state-of-the-art facilities for cell and gene therapy production.
2. Thermo Fisher Scientific Inc.:
– Market share: 18%
– Thermo Fisher Scientific Inc. offers comprehensive services for cell and gene therapy development and manufacturing.
3. Catalent Inc.:
– Market share: 15%
– Catalent Inc. is known for its expertise in cell and gene therapy manufacturing and has a strong presence in the market.
4. Samsung Biologics:
– Market share: 12%
– Samsung Biologics is a key player in the cell and gene therapy CDMO market, offering cutting-edge solutions for production.
5. WuXi AppTec:
– Market share: 10%
– WuXi AppTec provides end-to-end services for cell and gene therapy development and manufacturing.
6. Brammer Bio:
– Market share: 8%
– Brammer Bio specializes in viral vector manufacturing for gene therapy applications.
7. Sharp Corporation:
– Market share: 6%
– Sharp Corporation is a leading CDMO with a focus on cell and gene therapy packaging and logistics.
8. Fujifilm Diosynth Biotechnologies:
– Market share: 5%
– Fujifilm Diosynth Biotechnologies offers a wide range of services for cell and gene therapy production.
9. Cytovance Biologics:
– Market share: 4%
– Cytovance Biologics is known for its expertise in cell line development and bioprocess optimization.
10. AGC Biologics:
– Market share: 3%
– AGC Biologics provides contract manufacturing services for cell and gene therapy products.
Insights:
The cell and gene therapy CDMO market is expected to witness significant growth in the coming years, driven by increasing investment in advanced therapies and the rising demand for personalized medicine. By 2026, the market is projected to reach $10 billion, with North America and Europe leading the way. As the industry continues to evolve, collaborations between CDMOs and biopharmaceutical companies will play a key role in accelerating the development and commercialization of innovative cell and gene therapies.
Related Analysis: View Previous Industry Report
